丙泊酚相关严重不良事件:FAERS 数据库分析。

IF 6.5 3区 工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Biotechnology & Genetic Engineering Reviews Pub Date : 2024-11-01 Epub Date: 2023-04-17 DOI:10.1080/02648725.2023.2202541
Guocheng Xuan, Yi Zhang, Jinhua Cui, Jing Zhou, Cheng Sui
{"title":"丙泊酚相关严重不良事件:FAERS 数据库分析。","authors":"Guocheng Xuan, Yi Zhang, Jinhua Cui, Jing Zhou, Cheng Sui","doi":"10.1080/02648725.2023.2202541","DOIUrl":null,"url":null,"abstract":"<p><p>Propofol is an ultra-fast-acting intravenous anesthetic, which is rapidly metabolized primarily into inactive compounds in the live and then excreted in the urine. The purpose of this study is to explore the risk signals of propofol based on the US FDA Adverse Event Reporting System database. The risk signals of propofol-related adverse reactions in adverse event (AE) reports from 2004 to 2021 in the US FAERS were mined using ratio-report method (ROR) and the ratio-report ratio method (PRR) methods. We screened out 1651 pairs AE reports using propofol as primary suspect (PS) drugs. ROR, PRR, BCPNN and MGPS methods were used to calculate respectively, there are 363 positive preferred terms (PT) signals with 9549 cases. Among them, the top 3 adverse reactions associated with using propofol from the FAERS database were anaphylactic shock, hypotension and propofol infusion syndrome. The top 3 systems of the body associated with adverse reaction of propofol from the FAERS database were General disorders, Cardiac disorders and administration site conditions and Respiratory, thoracic and mediastinal disorders. The top 4 indication of using propofol from the FAERS database, including anaesthesia, induction of anaesthesia, sedation, general anaesthesia. There are many adverse reactions that are not included in the drug insert of propofol and involve a wide range of organs and/or systems. Caution should be exercised in the clinical use of propofol.</p>","PeriodicalId":55355,"journal":{"name":"Biotechnology & Genetic Engineering Reviews","volume":" ","pages":"2874-2887"},"PeriodicalIF":6.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Propofol-associated serious adverse events: an analysis of the FAERS database.\",\"authors\":\"Guocheng Xuan, Yi Zhang, Jinhua Cui, Jing Zhou, Cheng Sui\",\"doi\":\"10.1080/02648725.2023.2202541\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Propofol is an ultra-fast-acting intravenous anesthetic, which is rapidly metabolized primarily into inactive compounds in the live and then excreted in the urine. The purpose of this study is to explore the risk signals of propofol based on the US FDA Adverse Event Reporting System database. The risk signals of propofol-related adverse reactions in adverse event (AE) reports from 2004 to 2021 in the US FAERS were mined using ratio-report method (ROR) and the ratio-report ratio method (PRR) methods. We screened out 1651 pairs AE reports using propofol as primary suspect (PS) drugs. ROR, PRR, BCPNN and MGPS methods were used to calculate respectively, there are 363 positive preferred terms (PT) signals with 9549 cases. Among them, the top 3 adverse reactions associated with using propofol from the FAERS database were anaphylactic shock, hypotension and propofol infusion syndrome. The top 3 systems of the body associated with adverse reaction of propofol from the FAERS database were General disorders, Cardiac disorders and administration site conditions and Respiratory, thoracic and mediastinal disorders. The top 4 indication of using propofol from the FAERS database, including anaesthesia, induction of anaesthesia, sedation, general anaesthesia. There are many adverse reactions that are not included in the drug insert of propofol and involve a wide range of organs and/or systems. Caution should be exercised in the clinical use of propofol.</p>\",\"PeriodicalId\":55355,\"journal\":{\"name\":\"Biotechnology & Genetic Engineering Reviews\",\"volume\":\" \",\"pages\":\"2874-2887\"},\"PeriodicalIF\":6.5000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biotechnology & Genetic Engineering Reviews\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1080/02648725.2023.2202541\",\"RegionNum\":3,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/4/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology & Genetic Engineering Reviews","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/02648725.2023.2202541","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

异丙酚是一种超速效静脉麻醉剂,主要在体内迅速代谢为非活性化合物,然后随尿液排出体外。本研究的目的是根据美国 FDA 不良事件报告系统数据库,探讨异丙酚的风险信号。采用比值报告法(ROR)和比值报告比值法(PRR)挖掘了美国 FAERS 2004 年至 2021 年不良事件(AE)报告中丙泊酚相关不良反应的风险信号。我们筛选出了 1651 对以丙泊酚为主要可疑(PS)药物的 AE 报告。分别使用 ROR、PRR、BCPNN 和 MGPS 方法计算,共发现 363 个阳性首选术语(PT)信号,9549 个病例。其中,FAERS 数据库中与使用异丙酚相关的前 3 种不良反应是过敏性休克、低血压和异丙酚输注综合征。在 FAERS 数据库中,与使用异丙酚有关的不良反应排在前 3 位的身体系统是全身疾病、心脏疾病和给药部位疾病以及呼吸系统、胸部和纵隔疾病。在 FAERS 数据库中,使用异丙酚的四大适应症包括麻醉、麻醉诱导、镇静、全身麻醉。有许多不良反应未列入异丙酚的药品说明书,这些不良反应涉及多个器官和/或系统。在临床使用异丙酚时应谨慎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Propofol-associated serious adverse events: an analysis of the FAERS database.

Propofol is an ultra-fast-acting intravenous anesthetic, which is rapidly metabolized primarily into inactive compounds in the live and then excreted in the urine. The purpose of this study is to explore the risk signals of propofol based on the US FDA Adverse Event Reporting System database. The risk signals of propofol-related adverse reactions in adverse event (AE) reports from 2004 to 2021 in the US FAERS were mined using ratio-report method (ROR) and the ratio-report ratio method (PRR) methods. We screened out 1651 pairs AE reports using propofol as primary suspect (PS) drugs. ROR, PRR, BCPNN and MGPS methods were used to calculate respectively, there are 363 positive preferred terms (PT) signals with 9549 cases. Among them, the top 3 adverse reactions associated with using propofol from the FAERS database were anaphylactic shock, hypotension and propofol infusion syndrome. The top 3 systems of the body associated with adverse reaction of propofol from the FAERS database were General disorders, Cardiac disorders and administration site conditions and Respiratory, thoracic and mediastinal disorders. The top 4 indication of using propofol from the FAERS database, including anaesthesia, induction of anaesthesia, sedation, general anaesthesia. There are many adverse reactions that are not included in the drug insert of propofol and involve a wide range of organs and/or systems. Caution should be exercised in the clinical use of propofol.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biotechnology & Genetic Engineering Reviews
Biotechnology & Genetic Engineering Reviews BIOTECHNOLOGY & APPLIED MICROBIOLOGY-GENETICS & HEREDITY
CiteScore
6.50
自引率
3.10%
发文量
33
期刊介绍: Biotechnology & Genetic Engineering Reviews publishes major invited review articles covering important developments in industrial, agricultural and medical applications of biotechnology.
期刊最新文献
Application of Shouwu Yizhi prescription in decubation of patients with ischemic stroke. Analysis of non-targeted serum metabolomics in patients with chronic kidney disease and hyperuricemia. Clinical effect of laparoscopic cholecystectomy in the treatment of chronic cholecystitis with gallstones. Evaluating the value of progressive muscle relaxation therapy for patients with lumbar disc herniation after surgery based on a difference-in-differences model. Regulation of TREM2 on BV2 inflammation through PI3K/AKT/mTOR pathway.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1